Array BioPharma Inc. (ARRY) Touches $23.52 High on Mar, 5; BORR DRILLING LTD. ORDINARY SHARES BERM (BDRLF) SI Increased By 0.78%

Array BioPharma Inc. (NASDAQ:ARRY) Logo

The stock of Array BioPharma Inc. (NASDAQ:ARRY) reached all time high today, Mar, 5 and still has $24.70 target or 5.00% above today’s $23.52 share price. This indicates more upside for the $5.13B company. This technical setup was reported by . If the $24.70 PT is reached, the company will be worth $256.65M more. The stock decreased 0.57% or $0.14 during the last trading session, reaching $23.52. About 604,033 shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 33.98% since March 5, 2018 and is uptrending. It has outperformed by 29.61% the S&P500. Some Historical ARRY News: 06/03/2018 – BIOLINERX SEES PHASE 2A BL-8040, KEYTRUDA COMBO RESULTS 2H `18; 07/03/2018 – MERCK & CO – CO, ISAI TO DEVELOP AND COMMERCIALIZE LENVIMA JOINTLY, BOTH AS MONOTHERAPY AND IN COMBINATION WITH MERCK’S ANTI-PD-1 THERAPY, KEYTRUDA; 09/04/2018 – Keytruda is already approved to treat several forms of cancer, including advanced melanoma. The drug racked up $3.81 billion in revenue in 2017; 30/04/2018 – Merck Has Submitted Keytruda Combination For FDA Approval — MarketWatch; 10/04/2018 – NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB; 13/04/2018 – BRISTOL-MYERS SQUIBB- IN TRIAL, TWO SECONDARY ENDPOINTS OF ORR, MEDIAN DURATION OF RESPONSE DEMONSTRATED DURABILITY WITH OPDIVO VS DOCETAXEL; 15/04/2018 – Merck: Keytruda First Anti-PD-1 Therapy to Show Recurrence-Free Survival Benefit Across Stage IIIA, IIIB, IIIC Melanoma; 10/04/2018 – BerGenBio Completes Recruitment Into First Stage of Phase Il NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®; 09/04/2018 – KEYTRUDA MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3; 13/03/2018 – Merck Gets FDA Priority Review for Keytruda sBLA in Advanced Cervical Cancer

BORR DRILLING LTD. ORDINARY SHARES BERM (OTCMKTS:BDRLF) had an increase of 0.78% in short interest. BDRLF’s SI was 5.76 million shares in March as released by FINRA. Its up 0.78% from 5.71M shares previously. With 100 avg volume, 57553 days are for BORR DRILLING LTD. ORDINARY SHARES BERM (OTCMKTS:BDRLF)’s short sellers to cover BDRLF’s short positions. It closed at $2.72 lastly. It is down 0.00% since March 5, 2018 and is . It has underperformed by 4.37% the S&P500.

Borr Drilling Limited operates as a drilling contractor to the gas and oil industry worldwide. The company has market cap of $1.58 billion. As of December 31, 2017, the firm operated a fleet of 26 jack-up drilling rigs. It currently has negative earnings. It provides services to gas and oil exploration and production industry worldwide.

More notable recent Borr Drilling Limited (OTCMKTS:BDRLF) news were published by: which released: “BORR DRILLING LTD 2018 Q2 – Results – Earnings Call Slides – Seeking Alpha” on August 23, 2018, also with their article: “Borr Drilling: January 2019 Fleet Status Report And Valuation – Seeking Alpha” published on January 07, 2019, published: “Borr Drilling: Q3 Earnings And Fleet Status Report – Seeking Alpha” on November 23, 2018. More interesting news about Borr Drilling Limited (OTCMKTS:BDRLF) were released by: and their article: “Borr Drilling: A Market Leader In Modern Jack-Up Rigs With Long-Term Growth Visibility – Seeking Alpha” published on August 14, 2018 as well as‘s news article titled: “Borr Drilling Reactivates 4 Jack-Ups On Speculation – Seeking Alpha” with publication date: October 05, 2018.

Investors sentiment increased to 1.23 in 2018 Q4. Its up 0.32, from 0.91 in 2018Q3. It improved, as 19 investors sold Array BioPharma Inc. shares while 61 reduced holdings. 41 funds opened positions while 57 raised stakes. 205.04 million shares or 5.26% more from 194.80 million shares in 2018Q3 were reported. Rhenman & Prns Asset has 1.14% invested in Array BioPharma Inc. (NASDAQ:ARRY). Axa stated it has 0.03% in Array BioPharma Inc. (NASDAQ:ARRY). Aperio Grp Incorporated Lc holds 0% or 33,726 shares. Tekla Management reported 0.22% stake. Next Grp holds 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY) for 1,300 shares. Hanseatic Mgmt Svcs holds 0.22% or 11,448 shares in its portfolio. Apis Advsr Ltd Com reported 490,000 shares. Research And Management owns 100 shares for 0% of their portfolio. Marshall Wace Llp has 0.02% invested in Array BioPharma Inc. (NASDAQ:ARRY). Guggenheim Lc reported 202,847 shares stake. Morgan Stanley reported 0.01% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). The New York-based Mutual Of America Capital Mgmt Limited Liability Company has invested 0.03% in Array BioPharma Inc. (NASDAQ:ARRY). Canada Pension Plan Invest Board has 0.02% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 728,500 shares. Artal Grp Sa holds 1.32% or 2.50M shares in its portfolio. Kazazian Asset Management has 0.3% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 15,564 shares.

Among 3 analysts covering Array BioPharma (NASDAQ:ARRY), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Array BioPharma has $30 highest and $20 lowest target. $25’s average target is 6.29% above currents $23.52 stock price. Array BioPharma had 3 analyst reports since December 13, 2018 according to SRatingsIntel.

Since September 4, 2018, it had 2 buys, and 12 sales for $19.60 million activity. 18,000 shares were sold by VAN LUNSEN GIL J, worth $265,684. $2.38 million worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by Squarer Ron. 1,251 shares were sold by Oltmans Curtis Gale, worth $22,518. The insider Saccomano Nicholas A sold $4.04M. 96,712 Array BioPharma Inc. (NASDAQ:ARRY) shares with value of $2.11 million were sold by Haddock Jason. Sandor Victor sold $88,091 worth of stock or 6,268 shares. 3,000 shares valued at $50,595 were bought by COX CARRIE SMITH on Thursday, November 1.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $5.13 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

More notable recent Array BioPharma Inc. (NASDAQ:ARRY) news were published by: which released: “Here’s Why Array BioPharma (ARRY) is a Great Momentum Stock to Buy – Nasdaq” on February 05, 2019, also with their article: “Here’s What Sent Array BioPharma Soaring 11.3% Today – Nasdaq” published on February 05, 2019, published: “Health Care Sector Update for 02/05/2019: ARRY,HZNP,HAE – Nasdaq” on February 05, 2019. More interesting news about Array BioPharma Inc. (NASDAQ:ARRY) were released by: and their article: “Noteworthy Monday Option Activity: ARRY, NCR, ADSK – Nasdaq” published on February 04, 2019 as well as‘s news article titled: “Array: Poised For Growth – Seeking Alpha” with publication date: February 06, 2019.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.